cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011 ; 29 : 2011 – 2019 . 26. Hutchins G Southward K Handley K . Value of mismatch repair, KRAS, and BRAF mutations in predicting
Search Results
Sanam Loghavi, Mark J. Routbort, Keyur P. Patel, Rajyalakshmi Luthra, Wei-Lien Wang, Russell R. Broaddus, Michael A. Davies, and Alexander J. Lazar
Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann, and Lisa A. Gurski
with BRAF mutation–positive DTCs that are locally recurrent, advanced, and/or metastatic, are not surgically resectable, are not amenable to RAI, and are progressing and/or symptomatic (see PAP-9, page 1433). The decision was made to not specify BRAF
Axel Grothey and Alan P. Venook
from the IDEA study for adjuvant treatment of colon cancer. advanced disease. Tumors should be evaluated for KRAS, NRAS , and BRAF status, either individually or as part of a next-generation sequencing panel. KRAS and BRAF mutations are
Lindsey M. Charo, Adam M. Burgoyne, Paul T. Fanta, Hitendra Patel, Juliann Chmielecki, Jason K. Sicklick, and Michael T. McHale
neurodegenerative dementia 22 but are not well-associated with human cancer. According to several studies, approximately 1% of GISTs possess BRAF mutations, which are most often canonical V600E seen in other tumor types, including melanoma and colon cancer. 3
Anastasia Drobysheva, Laura J. Klesse, Daniel C. Bowers, Veena Rajaram, Dinesh Rakheja, Charles F. Timmons, Jason Wang, Korgun Koral, Lynn Gargan, Erica Ramos, and Jason Y. Park
); only 1 of the 17 patients had a BRAF mutation, and no patients had mutations in HRAS, KRAS, NRAS , or FGFR1 on targeted analysis. 18 Frequent MAPK pathway activation through fusion and nonfusion mutations has been recognized as a potential target
Kristin K. Deeb, Jakub P. Sram, Hanlin Gao, and Marwan G. Fakih
BRAF mutations in colorectal cancer have been incorporated into oncology practice for cetuximab and panitumumab therapy since 2008. 26 High-throughput technologies using NGS that enable massively parallel sequencing of nucleic acid (DNA and RNA) at a
Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming
anti-EGFR therapy in patients with tumors harboring KRAS, NRAS , and BRAF mutations, which are commonly enriched within the right-sided primary population. 25 – 27 When stratified for sidedness, prospective targeted sequencing panels have revealed
Daniel G. Coit and Anthony J. Olszanski
median overall survival was 13.6 versus 9.7 months, respectively ( P <.001). 11 , 12 Up to 50% of patients with the BRAF mutation show a response to this drug; however, the typical duration of response is approximately 6 months, due to the emergence
Presenters: Douglas B. Johnson, Susan M. Swetter, April K.S. Salama, and Evan Wuthrick
dramatic improvement in relapse-free survival versus placebo. 5 “It’s debated whether BRAF/MEK inhibition or anti–PD-1 is a better treatment option in the adjuvant setting, but it’s certainly clinically indicated to test for BRAF mutations in the stage
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass
there are not enough data from IDEA to draw any conclusions for patients with rectal or stage II colon cancer. Treatment of RAS Wild-Type/ BRAF Mutation–Positive Metastatic CRC In the 2017 version of the NCCN Guidelines, patients with
